Effect of Magnesium Sulphate in treatment of preterm labour

Does Magnesium Sulphate delays active phase of labour in women with premature rupture of membranes? A randomized control trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012091810876N1

Enrollment

Registered

2012-11-04

Start date

2011-12-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premature preterm ruptureof membran with preterm labur. Delayed delivery after spontaneous or unspecified rupture of membranes

Interventions

Intervention 1: Administration Magnesium Sulphate in intervention group start by 4 gr in 100 cc ringer lactat in 20 minuts and continue 2gr /hour until 12-24 hr afer inhibit uterin contraction. We us

Treatment - Drugs

Administration Magnesium Sulphate in intervention group start by 4 gr in 100 cc ringer lactat in 20 minuts and continue 2gr /hour until 12-24 hr afer inhibit uterin contraction. We used Magnesium Sul

We used Normal Salin infusion in control group the same as Magnesium Sulphate serum.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Inclusion criteria were: (a) pregnant women with gestational age below 34 weeks who were hospitalized for premature rupture and labour complaints; (b) the absence of concomitant disease such as chorioamnionitis or a history of drug sensitivity to magnesium sulphate; (c) no previous use of magnesium sulphate in order to curb labour complaint in recent pregnancy; (d) the absence of twin or multiple pregnancy. Exclusion criteria also were: (a) probable case of chorioamnionitis; (b) progress of labour as 4 cm cervical dilatation; (c) allergy or medical complications in combination with magnesium sulphate; (d) fatal foetal anomalies; (e) Nonreassuring fetal status; (f) severe foetal growth restriction; (g); Severe preeclampsia or eclampsia; (h) Maternal haemorrhage with hemodynamic instability

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Chorioamnionitis. Timepoint: Hourly. Method of measurement: Measurement of mother's tempreture with termometer &measurement mother's and fetal heart rate.	—

Secondary

Measure	Time frame
RDS. Timepoint: After birth. Method of measurement: Clinical evaluation.;IVH. Timepoint: After birth. Method of measurement: Clinical data.;NICU admition. Timepoint: After birth. Method of measurement: Subjective.;Sepsis. Timepoint: After birth. Method of measurement: Clinical data.;Fetal death. Timepoint: After birth. Method of measurement: Clinical data.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactdr Soraya Saleh Gargari

Shahid Beheshti Medical university

soraya_saleh2000@yahoo.co.uk+98 21 5506 2628

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 7, 2026